{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":28,"n_cols":5,"rows_kept":28,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[15,2,15,3],[16,2,16,3],[18,2,18,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910523903503321"]
[null,null,"Titolo",null,"Interdisciplinary Approaches to Overlap Disorders in Dermatology & Rheumatology / / edited by Amit Garg, Joseph F. Merola, Laura Fitzpatrick"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer International Publishing : , : Imprint : Springer, , 2022"]
[null,null,"ISBN",null,"3-319-18446-6"]
[null,null,"Edizione",null,"[1st ed. 2022.]"]
[null,null,"Descrizione fisica",null,"1 online resource (297 pages)"]
[null,null,"Collana",null,"Medicine Series"]
[null,null,"Disciplina",null,"616.5"]
[null,null,"Soggetti",null,"Dermatology"]
[{"$nulls":4},"Internal medicine"]
[{"$nulls":4},"Internal Medicine"]
[{"$nulls":4},"Malalties de la pell"]
[{"$nulls":4},"Dermatologia"]
[{"$nulls":4},"Reumatologia"]
[{"$nulls":4},"Llibres electrònics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,"Nota di contenuto",null,"Intro -- Foreword -- Preface -- Contents -- Contributors -- 1: Evaluation of the Integumentary and Musculokeletal Systems: An Approach to the Interdisciplinary Examination for Overlap Diseases -- Introduction -- General Recommendations -- Distribution -- Color -- Shape or Configuration -- Scaling -- Consistency -- Scalp/Hair/Nails/Oral Mucosa -- Rheumatologic Musculoskeletal Examination -- Joint Examination -- Muscle Examination -- Conclusion -- 2: Serologic Evaluation in the Rheumatology-Dermatology Overlap Patient -- Interdisciplinary Introduction -- Erythrocyte Sedimentation Rate and C-reactive Protein -- Antibodies in Rheumatologic Disease - General Principles -- Anti-nuclear Antibody -- SLE-Associated Serologies -- Systemic Sclerosis (Scleroderma) -- Dermatomyositis -- Psoriatic Arthritis -- Vasculitis -- Still's Disease -- Sarcoidosis -- Lyme disease -- Summary -- Suggested Reading -- References -- 3: Cutaneous Lupus -- Interdisciplinary Introduction -- Epidemiology &amp -- Classification -- Epidemiology -- Classification of Cutaneous Lupus Erythematosus -- Gilliam Classification (Table 3.1) -- Other Approaches to CLE Subgrouping -- LE-Nonspecific Skin Changes "]
[{"$nulls":4},"(Table 3.2) -- CLE Association with SLE -- Pathogenesis of Cutaneous Lupus Erythematosus -- Genetic Factors -- Ultraviolet Light and Apoptosis -- Innate Immunity -- Inflammatory Cells -- Inflammatory Cytokines and Chemokines -- Clinical Features -- Acute Cutaneous Lupus Erythematosus (ACLE) -- Subacute Cutaneous Lupus Erythematosus (SCLE) -- Discoid Lupus Erythematosus (DLE) -- Cutaneous Lupus: Additional LE-Specific Skin Variants -- Lupus Erythematosus Tumidus (Tumid Lupus) -- Lupus Erythematosus Panniculitis/Lupus Profundus -- Chilblain Lupus -- Neonatal Lupus -- Lupus-specific Vesiculobullous Disease -- Bullous SLE (BSLE)."]
[{"$nulls":4},"Vesiculobullous Disease Occurring as Severe Variants of ACLE, SCLE, and Rarely, DLE. -- Non-specific Cutaneous Lesions of LE -- Diagnostic Considerations -- Diagnosis of Cutaneous Lupus -- Histopathology -- Antibody Deposits in the Skin (DIF) -- Autoantibodies -- Evaluation for Systemic Disease -- Principles of Management -- Prevention/Patient Education -- Sun Protection -- Smoking Cessation -- Camouflage -- Local Therapy -- Topical Steroids -- Calcineurin Inhibitors -- Intralesional corticosteroids -- Laser -- Systemic Therapy -- Antimalarials -- Antimalarial-resistant Disease -- Immunosuppressant Agents -- Methotrexate -- Mycophenolate Mofetil (MMF) or Mycophenolate Sodium -- Azathioprine -- Systemic Corticosteroids -- Immunomodulators -- Dapsone -- Thalidomide -- Lenalidomide -- Oral Retinoids -- Other Therapies -- Disease and Comorbidity Assessment (Table 3.6) -- Systemic Screening -- Malignancy Risk -- Pregnancy -- Summary -- References -- 4: Dermatomyositis -- Interdisciplinary Introduction -- Epidemiology and Risk Factors -- Classification -- Clinical Presentation -- Skin Disease -- Classic Features -- Rare Presentations of Cutaneous DM -- Cutaneous Signs of Interstitial Lung Disease -- Cutaneous Signs of Internal Malignancy -- Histopathology -- Differential Diagnosis -- Muscle Disease -- Classic Presentation -- Histopathology -- Electromyography -- Imaging -- Differential Diagnosis -- Systemic Disease -- Pulmonary Manifestations -- Interstitial Lung Disease -- Pulmonary Arterial Hypertension -- Cardiac Manifestations -- DM-Specific Cardiac Involvement -- Coronary Artery Disease -- Thromboembolic Disease -- Joint Manifestations -- Renal Manifestations -- Rare Manifestations -- Cancer -- Principles of Management -- Overview -- Behavioral Change -- Physical Medicine and Rehabilitation -- Topical Agents -- Topical Corticosteroids."]
[{"$nulls":4},"Topical Calcineurin Inhibitors -- Systemic Medications -- Antimalarials -- Methotrexate -- Systemic Corticosteroids -- Mycophenolate Mofetil -- Intravenous Immunoglobulin -- Rituximab -- Cyclosporine -- Tofacitinib -- Tacrolimus -- Nonsteroidal Anti-inflammatory Drugs -- Azathioprine -- Leflunomide -- Dapsone -- Thalidomide -- Cyclophosphamide -- Special Cases: Calcinosis Cutis and Ulceration -- Summary -- References -- 5: Morphea -- Interdisciplinary Introduction -- Nomenclature -- Epidemiology -- Pathogenesis -- Evidence for Autoimmunity -- Genetic Susceptibility -- Environmental Triggers -- Histopathology -- Classification -- Peterson Criteria (1995) -- Laxer and Zulian (2006) -- Clinical Features -- Plaque Morphea -- Generalized Morphea -- Linear Morphea -- Deep Morphea -- Disabling Pansclerotic Morphea -- Eosinophilic Fasciitis -- Mixed Morphea -- Rare Variants -- Natural History -- Disease Assessment -- Comorbidities -- Approach to Screening and Monitoring -- Principals of Management -- Topical Therapy -- Phototherapy -- Systemic Therapy -- Summary -- References -- 6: Systemic Sclerosis -- Interdisciplinary Introduction -- Nomenclature -- Epidemiology -- SSc Classification Criteria -- SSc Subsets -- Clinical Features -- Cutaneous "]
[{"$nulls":4},"-- Vascular -- Raynaud's Phenomenon -- Digital Ischemia -- Gastrointestinal -- Oropharynx -- Esophagus -- Gastric -- Small Intestine -- Large Intestine and Anorectum -- Liver -- Pulmonary -- Interstitial Lung Disease -- Pulmonary Hypertension -- Cardiac -- Renal -- Musculoskeletal -- Pathophysiology of Systemic Sclerosis -- Vascular Injury and the Initiation of SSc -- Autoimmunity -- Fibrosis -- Risk Factors for Systemic Sclerosis -- Genetic Risk Factors -- Occupational and Environmental Risk Factors -- Autoantibodies -- Diagnostic Considerations -- Physical Examination -- Laboratory Testing -- Cardiopulmonary Studies."]
[{"$nulls":4},"Other Studies -- Disease and Comorbidity Assessment -- Measurement of Disease Activity and Severity -- Monitoring -- Comorbidities -- Management of SSc -- Organ-Specific Therapy -- Skin Disease -- Vascular: Raynaud's Phenomenon and Digital Ischemic Ulcers -- Gastrointestinal -- Pulmonary -- Interstitial Lung Disease -- Pulmonary Arterial Hypertension -- Renal -- Musculoskeletal -- Immune Modulation and Targeted Therapies -- Survival -- Summary -- References -- 7: Psoriasis and Psoriatic Arthritis -- Interdisciplinary Introduction -- Epidemiology &amp -- Classification -- Pathogenesis -- Clinical Features -- Diagnostic Considerations -- Screening Tools -- Disease and Comorbidity Assessment -- Gastrointestinal Disease -- Autoimmune Ophthalmic Disease -- Psychiatric Disease -- Metabolic Syndrome and Cardiovascular Disease -- Principles in Management -- Disease Outcome Measures -- Minimal Disease Activity State and Treat to Target -- Therapeutic Interventions -- Lifestyle Modifications -- Topical Therapy for Psoriasis -- Phototherapy -- Oral Therapy -- Non-steroidal Anti-inflammatory Drugs and Corticosteroids -- Methotrexate -- Leflunomide -- Sulfasalazine -- Acitretin -- Cyclosporine -- Apremilast -- Biologic Therapy -- TNF-α Antagonists -- Etanercept -- Adalimumab -- Infliximab -- Golimumab -- Certolizumab -- Risks and Benefits of Using TNF-α Antagonists -- IL-12 / IL-23 Antagonists -- Ustekinumab -- Guselkumab -- Risankizumab and Tildrakizumab -- Safety Concerns with IL-12/23 Antagonists -- IL-17 Antagonists -- Secukinumab -- Ixekizumab -- Brodalumab -- Safety Concerns with IL-17 Antagonists -- Janus Kinase Inhibitors -- Safety Concerns with JAK Inhibitors -- T Cell Costimulation Blockade -- Safety Concerns with T Cell Co-stimulation Blockade -- Monitoring in Biologics -- Combining Psoriasis Therapies."]
[{"$nulls":4},"Cost of Psoriasis and Psoriatic Arthritis Therapies -- References -- 8: Vasculitis -- Interdisciplinary Introduction -- Nomenclature and Classification of Vasculitis -- Pathophysiology and Clinical Features -- Small-Vessel Vasculitis -- Medium-Vessel Vasculitis -- Extracutaneous Manifestations -- Types of Vasculitis with Skin Involvement -- Cutaneous Small-Vessel Vasculitis/Small-Vessel Vasculitis of the Skin -- Cutaneous Manifestations -- Systemic Findings -- IgA Vasculitis -- Cutaneous Manifestations -- Systemic Findings -- Urticarial Vasculitis -- Cutaneous Manifestations -- Systemic Findings -- Cryoglobulinemic Vasculitis -- Cutaneous Manifestations -- Systemic Findings -- Granulomatosis with Polyangiitis (Wegner's) -- Cutaneous Manifestations -- Systemic Findings -- Microscopic Polyangiitis -- Cutaneous Manifestations -- Systemic Findings -- Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) -- Cutaneous Manifestations -- Systemic Findings -- Polyarteritis Nodosa -- Cutaneous Manifestations -- Systemic Findings -- Giant Cell Arteritis and Takayasu Arteritis -- Initial Evaluation of Patients with Possible Vasculitis -- Skin Biopsy -- Biopsy Selection and Performance -- Histologic Findings in Cutaneous Vasculitis -- Common Pitfalls in Using Skin Pathology to Evaluate Possible Vasculitis "]
[{"$nulls":4},"-- Review of Systems and Medical History -- Laboratory Studies -- Basic Tests That Should Be Ordered in All Patients -- Urinalysis with Microscopic Examination -- Basic Metabolic Panel -- Complete Blood Count -- Other Laboratory Tests Useful in Select Cases -- Liver Function Tests -- Acute Phase Reactants -- Serologic Tests of Autoimmunity -- Antineutrophilic Cytoplasmic Antibodies (ANCAs) -- Anti-Nuclear Antibodies -- Rheumatoid Factor -- Complement Levels -- Cryoglobulins -- Serum Protein Electrophoresis (SPEP) and Immunofixation."]
[{"$nulls":4},"Serologic Tests for Infections."]
[null,null,null,"Sommario/riassunto","This comprehensive textbook provides physicians with a practical evidence-based framework to evaluate and manage patients suspected of having overlap disorders involving the integumentary, musculoskeletal and related systems. The book discusses hallmark mucocutaneous features which support, and often specify, diagnosis, and it provides a summary of relevant multisystem examinations, serologic workup, and imaging. Interdisciplinary perspectives on treatment also facilitate a streamlined approach to referral and co-management. Interdisciplinary Approaches to Overlap Disorders in Dermatology & Rheumatology is a must-have resource for dermatologists, rheumatologists, internists, as well as students of medicine and trainees across medical specialties. ."]